Ten patients with low grade non-Hodgkin's lymphoma (seven foUlicular small cleaved and three small lymphocytic) were treated with 1 [tg oral alfacalcidol (lat-hydroxycholecalciferol) daily. Of the seven patients with lymphomas of follicular small cleaved subtype, one achieved complete and three partial remission, whereas none of three patients with small lymphocytic lymphomas responded. In seven of the 10 patients, 1,25(OH)2D, receptors were measured in tissue from lymph nodes, and a positive correlation between the presence and amount of receptor and response to alfacalcidol was found.
Introduction
Low grade non-Hodgkin's lymphomas as defined in the working formulation of non-Hodgkin's lymphomas' consist of the following histological subtypes: small lymphocytic, follicular small cleaved cell, and follicular mixed small cleaved cell and large cell. They account for 30-45% of all lymphomas and are generally very responsive to single agent or combination chemotherapy.2 With the possible exception of the follicular mixed small cleaved cell and ROBERT A COWAN, GORDON J FORREST, large cell subtype,' however, the remission of disease obtained with such chemotherapy is not durable, and a pattern ofcontinual relapse has been identified.4 Thus although these tumours are compatible with long survival they can rarely be cured, and delaying the introduction of chemotherapy until it is clinically indicated is unlikely to compromise survival. During and during treatment. In case 1 the patient had mild hypercalcaemia (2-7 mmol/l; 10-8 mg/100 ml) for eight weeks after treatment with alfacalcidol was begun, which spontaneously returned to normal values. The treatment had no other toxic effects. Two patients (cases 9 and 10) had raised white cell counts before treatment (61 x 109/l and 253 x 109/l) due to a mature lymphocytosis consistent with an exfoliating small lymphocytic lymphoma. As the lymphadenopathy in these patients increased during treatment with la-OHD, the white cell count rose further.
Discussion
In this study we showed that alfacalcidol had considerable antitumour activity in the treatment of low grade non-Hodgkin's lymphoma. This effect was restricted to the patients with lym-phoma of follicular small cleaved cell subtype, but this may reflect the small number of patients with the small lymphocytic subtype studied. Some correlation seemed to exist, however, between the presence and amount of 1,25(OH)2D, receptor and subsequent response to alfacalcidol. This is important, as this receptor state may ultimately be used to determine a patient's suitability for treatment with alfacalcidol. The duration of treatment required to induce regression of the tumour ranged from three to 16 weeks. Therefore, in the absence of progressive disease or toxicity, we recommend that treatment should be continued for a minimum of six months. Increasing the dose of alfacalcidol to more than 1 Ftg daily could add to toxicity, but we believe that it may be worth trying this in patients with low receptor concentrations who do not respond to 1 ,tg daily and those who respond but then relapse.
The precise mechanism by which alfacalcidol produced regression of the tumours in our patients is not clear. Regression may have been mediated through a differentiation effect, analogous to that observed with the human leukaemia cell line, in which leukaemia cells were transformed into monocytes by culture with 1,25(OH)2D3.5 It has also been shown, however, that 1,25(OH)2D, inhibits the production of interleukin 2, a T lymphocyte growth factor, by activated human T lymphocytes'6 and that it can suppress the proliferation of and production of immunoglobulin by normal peripheral mononuclear cells.' Thus it is possible, though speculative, that for lymphomas with 1 ,25(OH)2D3 receptors 1 ,25(OH)2D, is an inhibitory growth regulator, mediated by suppression of production of interleukin 2.
Spontaneous regression of tumours is well documented in low grade non-Hodgkin's lymphoma,5 and it could be argued that the responses to alfacalcidol in this study were simply manifestations of this phenomenon. Spontaneous remission of the magnitude that occurred in our patients would, however, be extremely unusual; a previous review reported an incidence of 5%, generally in untreated patients.'8 Horning and Rosenberg described spontaneous remission in 23% of 83 patients with low grade lymphomas, and in a group with the follicular small cleaved cell subtype the figure was as high as 30%,' but the median time to regression was long (eight months) and the patients were highly selected: none had had chemotherapy, and they were included in the study only because at presentation they did not require treatment with chemotherapy.
In our patients there was some evidence that the regression of tumours was due to alfacalcidol, such as the presence of receptors in those who responded and the absence or low level of receptors in those who did not and a fairly good temporal relation between the introduction of alfacalcidol and response. It is interesting to speculate that the spontaneous regression described by Horning and It is important to recognise that this increasingly used drug may cause severe hyperglucagonaemia to prevent patients treated with danazol undergoing unnecessary investigations to localise glucagonoma.
Introduction
Grossly increased plasma glucagon concentrations (>50 pmol/l (>17 4 ng/ml)) were found fortuitously in a woman receiving danazol for premenstrual exacerbations of lupus erythematosus. Known causes of hyperglucagonaemia were excluded. Glucagon concentrations were found to parallel the dosage of danazol, suggesting that hyperglucagonaemia was due to the drug. To explore this possibility we measured plasma glucagon concentrations during an oral glucose tolerance test in seven women taking danazol and six healthy controls.
Patients, methods, and results
Seven women aged 20-45 (mean 33 9) years treated with danazol (100-600 mg/day for four to 24 weeks) for endometriosis (five patients) or mastalgia (two patients) were randomly selected from the gynaecological outpatient clinic. One patient was taking phenobarbitone and lorazepam for epilepsy and another norethisterone 20 mg/day. Body weight ranged from 45-5 to 82-7 kg (mean 62-7 kg). The six control women did not differ noticeably from the group treated with danazol in either age (range 23-40, mean 2918 years) or body weight (range 50 to 68 kg, mean 58-3 kg); one was taking an oral contraceptive.
